Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Encysive Pharmaceuticals (ENCY) -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (13)	1/9/2006 10:51:13 AM
From: tuck	Respond to of 205

Got it, thanks. Here's the start of a trial of TBC3711 -- its very specific endothelin A receptor anatagonist -- for resistant hypertension. Much bigger market than PAH, I'd imagine. This appears to be a PI. >>HOUSTON, Jan. 9 /PRNewswire-FirstCall/ -- Encysive Pharmaceuticals (Nasdaq: ENCY - News) today announced the initiation of enrollment in a dose ranging study of TBC3711, the Company's next-generation, highly selective endothelin receptor antagonist. The 12-week, multi-center, randomized, double-blind, placebo-controlled study will evaluate four once-daily, oral doses of TBC3711 in approximately 150 patients with resistant hypertension. "As we focus on the anticipated approval and commercialization of Thelin(TM), we continue to step-up activities surrounding our pipeline to fuel the Company's long-term growth," commented Bruce D. Given, M.D., President and Chief Executive Officer of Encysive Pharmaceuticals. "Dose ranging TBC3711 is a top priority for the Company, and we see resistant hypertension as an excellent model for doing so." Study Details Diagnosed resistant hypertension patients enrolled in the study will be randomized to one of four double-blind TBC3711 treatment arms or a placebo arm. Each arm will consist of approximately 30 patients. All study arms will receive once-daily doses of either TBC3711 or placebo. TBC3711 or placebo will be given concomitantly with each patient's current anti-hypertensive regimen. Primary outcome data will consist of blood pressure measurements taken pre-dose and two hours post-dose. About TBC3711 and Resistant Hypertension TBC3711 is a small molecule that blocks the action of endothelin, a potent mediator of blood vessel constriction and growth of smooth muscle in vascular walls. Endothelin receptor antagonists may prove effective in the treatment of a variety of diseases where the regulation of vascular constriction is important, including resistant hypertension. TBC3711 is a next-generation endothelin A antagonist which possesses high oral bioavailability and is even more selective and potent than Thelin(TM), Encysive's pulmonary arterial hypertension treatment. TBC3711 is greater than 100,000-fold selective in the targeting of the endothelin A receptor versus the endothelin B receptor. Hypertension (blood pressure of 140/90 mmHg or higher) affects approximately 50 million individuals in the United States and approximately 1 billion individuals worldwide. A direct relationship exists between increased blood pressure and risk of heart attack, stroke, kidney disease and heart failure. Many individuals can successfully lower blood pressure through lifestyle modifications and/or treatment with one or more approved hypertension drugs. Resistant hypertension is defined as the failure to reach goal blood pressure (<140/90 mmHg) in patients who are adhering to a regimen of full doses of three anti-hypertensive drugs, including a diuretic.<< snip Sold some puts as '05 ended; they're doing well. Cheers, Tuck